세계의 수두 바이러스 백신 시장 규모 : 백신별, 용도별, 제공업체별, 지역 범위별, 예측

Varicella Virus Vaccine Market Size And Forecast

Varicella Virus Vaccine Market size was valued at USD 3536.52 Million in 2024 and is projected to reach USD 5443.44 Million by 2032, growing at a CAGR of 6.11% during the forecast period 2026-2032.

Global Varicella Virus Vaccine Market Drivers

The market drivers for the Varicella Virus Vaccine Market can be influenced by various factors. These may include:

• Growing Rates of Herpes Zoster and Varicella The need for varicella virus vaccines is driven by the rising global prevalence of herpes zoster and varicella infections. Because varicella is very communicable, especially in youngsters, and because those who have had varicella before might have herpes zoster, immunization is necessary to prevent both illnesses.
• Government Immunization Programs: The uptake of varicella virus vaccinations is largely influenced by government-led immunization programs, especially in industrialized and developing nations. Routine varicella vaccination for children, adolescents, and adults is frequently included in national immunization regimens, which boosts vaccine uptake and market demand.
• Health Authorities' Guidelines and Recommendations: The World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and other national health agencies have released guidelines and recommendations that support the use of varicella virus vaccines as a preventative measure against varicella and herpes zoster. Healthcare providers contribute to market growth by adhering to these recommendations.
• Varicella virus vaccines are now safer, more effective, and more convenient because to ongoing developments in vaccine technology, such as the creation of recombinant and live attenuated vaccines. Improved properties of more recent formulations boost market growth and uptake.
• Combination Vaccines: Patients and healthcare professionals find it more convenient and compliant when there are combination vaccines available that offer protection against several diseases, such as varicella, measles, mumps, rubella, and other diseases that can be prevented by vaccination. The varicella virus vaccine industry is growing in part because to combination vaccinations.
• Increasing Knowledge of the Benefits of Vaccination: Raising knowledge of the advantages of vaccination, such as its ability to avoid complications connected to varicella, such as encephalitis, pneumonia, and subsequent bacterial infections, promotes vaccination uptake in both individuals and parents. Campaigns for public health and educational programs support immunization as a preventative approach.
• Increasing Vaccination Coverage: Market expansion is fueled by initiatives to increase vaccination rates, especially in underprivileged groups and areas with high rates of disease. Varicella virus vaccinations are more widely available and disease transmission is decreased through targeted vaccination campaigns, school-based immunization programs, and outreach activities.
• Economic Benefits of Vaccination: By lowering healthcare expenses related to disease treatment, hospitalization, and lost productivity due to illness, vaccination against varicella and herpes zoster delivers financial benefits. Studies on health economics show that immunization against the varicella virus is affordable, which encourages market expansion.
• Growing Healthcare Expenditure: As a result of variables including population expansion, aging populations, and the development of a more advanced healthcare infrastructure, there is a greater ability to invest in preventative healthcare measures like vaccinations. Increased investment in healthcare facilitates the growth of the varicella virus vaccine market.
• Global Vaccine-Preventable Disease activities: Global activities to prevent and control vaccine-preventable diseases, such as varicella, have a positive impact on market growth. Governments, international organizations, and vaccine producers work together to make varicella virus vaccinations more accessible in high-risk areas.

Global Varicella Virus Vaccine Market Restraints

Several factors can act as restraints or challenges for the Varicella Virus Vaccine Market. These may include:

• Limited Vaccination Coverage: Although vaccinations against varicella virus are available, rates of vaccination may fluctuate throughout populations and geographical areas. Uptake and coverage rates can be hampered by elements including vaccine reluctance, false information, and a lack of understanding of the significance of immunization.
• Regulatory Difficulties: Getting regulatory clearance for vaccinations against the varicella virus can be difficult and time-consuming. The expense and time required for vaccine research and commercialization may increase due to regulatory requirements such as clinical trials, post-marketing surveillance, and safety and efficacy assessments.
• Problems with Vaccine Distribution and Supply: It can be difficult to guarantee a sufficient and steady supply of varicella virus vaccinations to satisfy demand. The availability of vaccines may be impacted by manufacturing setbacks, supply chain disruptions, and distribution issues, especially in areas with inadequate healthcare resources and infrastructure.
• High Manufacturing Costs: Specialized manufacturing techniques and strict quality control methods are required in the production of varicella virus vaccines. The price and accessibility of vaccines can be impacted by high manufacturing costs, which include investments in facilities, equipment, and raw materials, especially in low- and middle-income nations.
• Cold Chain Requirements: To preserve potency and efficacy, varicella virus vaccinations, like many others, need to be strictly temperature-controlled throughout the cold chain. Cold chain logistics, which include handling, storage, and transportation, can present logistical difficulties and raise expenses for producers and distributors of vaccines.
• Competition from Alternative vaccinations: Immunization plans for preventing varicella (chickenpox) and alternative vaccinations provide a threat to varicella viral vaccines. The market demand for stand-alone varicella vaccinations may be impacted by certain nations' decision to use combination vaccines, which provide protection against several diseases.
• Disease Epidemiology and Demographic Trends: Varicella (chickenpox) is a disease whose epidemiology can alter over time and between geographical areas due to a variety of factors, including population density, vaccine coverage rates, and demographic shifts. Varicella epidemiological shifts or declining disease prevalence might affect market dynamics and vaccination demand.
• Vaccine Safety Concerns: Adverse occurrences or safety concerns related to varicella virus vaccines have the potential to erode public confidence in immunization campaigns. Maintaining vaccination acceptance and uptake requires addressing safety concerns, carrying out stringent post-marketing surveillance, and being open and honest with healthcare practitioners and the general public.
• Healthcare Budget Restraints: Government financing and investment in varicella vaccination programs may be restricted due to competing healthcare objectives and budgetary restrictions. Inadequate financial resources may prevent underprivileged populations from getting vaccines and impede efforts to increase immunization rates.
• Pandemics and infectious disease outbreaks are examples of global health emergencies that might impede regular immunization programs and take funds away from efforts to vaccinate against varicella. Public health emergencies may also lead to a boost in vaccination demand, further taxing healthcare systems and vaccine supply networks.

Global Varicella Virus Vaccine Market Segmentation Analysis

The Global Varicella Virus Vaccine Market is Segmented on the basis of Vaccine Type, Application, End-User, and Geography.

Varicella Virus Vaccine Market, By Vaccine Type

• Monovalent Varicella Vaccine: A vaccine containing only the varicella zoster virus antigen, used for the prevention of varicella (chickenpox) infection.
• Combination Vaccines: Varicella vaccine may also be included in combination vaccines along with other antigens, such as measles, mumps, and rubella (MMR vaccine) or measles, mumps, rubella, and varicella (MMRV vaccine).

Varicella Virus Vaccine Market, By, Application

• Routine Immunization: Varicella vaccine is administered as part of routine childhood immunization schedules in many countries to prevent chickenpox.
• Outbreak Control: Varicella vaccine may be used in outbreak situations to control the spread of chickenpox in schools, communities, or other settings.
• Travel Vaccination: Varicella vaccine may be recommended for individuals traveling to regions where chickenpox is more common or for specific travel-related purposes.
• Post-Exposure Prophylaxis: Varicella vaccine may be given to susceptible individuals after exposure to varicella-zoster virus (VZV) to prevent or attenuate infection.

Varicella Virus Vaccine Market, By End-User

• Pediatric Clinics: Healthcare facilities specializing in pediatric care where varicella vaccine is administered to children as part of routine immunization schedules.
• Family Medicine Clinics: Healthcare facilities offering primary care services where varicella vaccine may be administered to children and adults.
• Public Health Departments: Government agencies responsible for public health initiatives, including vaccination programs and outbreak response.
• Travel Clinics: Specialty clinics providing travel-related health services where varicella vaccine may be offered to travelers.
• Pharmacies: Retail pharmacies or community health centers where varicella vaccine may be available for administration.

Varicella Virus Vaccine Market, By Geography

• North America: Includes the United States and Canada, where varicella vaccine is routinely administered as part of childhood immunization schedules.
• Europe: Includes countries such as Germany, the UK, France, Italy, and Spain, where varicella vaccine availability and usage may vary.
• Asia-Pacific: Includes countries such as China, Japan, India, and Australia, where varicella vaccine may be recommended for specific populations or in certain regions.
• Latin America: Includes countries such as Brazil, Mexico, and Argentina, where varicella vaccine may be included in national immunization programs.
• Middle East and Africa: Regions where varicella vaccine availability and usage may be limited or targeted towards specific populations.

Key Players

The "Global Varicella Virus Vaccine Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as Bio-Med Pvt. Limited, Changchun BCHT Biotechnology Co. Ltd., Emcure Pharmaceuticals Limited, GlaxoSmithKline plc, Green Cross Holdings (GC Pharma), Merck & Co. Inc., Mitsubishi Chemical Holdings Corporation, Novo Medi Sciences Pvt. Ltd., Sanofi, and Takeda Pharmaceutical Company Limited. The competitive landscape section includes key development strategies, market share analysis, and market positioning analysis of the aforementioned competitors internationally. Additionally, our market analysis includes a part devoted explicitly to these leading players. Our experts give an overview of each player's financial statements, product benchmarking, and SWOT analysis.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL VARICELLA VIRUS VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL VARICELLA VIRUS VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL VARICELLA VIRUS VACCINE MARKET, BY VACCINE

• 5.1 Overview
• 5.2 Monovalent Varicella Vaccine
• 5.3 Combination Varicella Vaccine

6 GLOBAL VARICELLA VIRUS VACCINE MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Chickenpox immunization
• 6.3 Herpes Zoster Immunization
• 6.4 Mumps
• 6.5 Measles
• 6.6 Rubella
• 6.7 Varicella (MMRV) Immunization

7 GLOBAL VARICELLA VIRUS VACCINE MARKET, BY PROVIDER

• 7.1 Overview
• 7.2 Public Provider
• 7.3 Private Provider

8 GLOBAL VARICELLA VIRUS VACCINE MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL VARICELLA VIRUS VACCINE MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Bio-Med Pvt. Limited
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Changchun BCHT Biotechnology Co. Ltd.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Emcure Pharmaceuticals Limited
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 GlaxoSmithKline plc
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Green Cross Holdings (GC Pharma)
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Merck & Co. Inc.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Development
• 10.7 Mitsubishi Chemical Holdings Corporation
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Novo Medi Sciences Pvt. Ltd.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Sanofi
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Development
• 10.10 Takeda Pharmaceutical Company Limited
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Development

11 Appendix

• 11.1 Related Research